Danaher Corp. (DHR) – GE Biopharma acquisition will lead to the growth in future

in on June 11, 2019

DHR sales grew by 4% to $4.9bn in Q1FY19 with 5.5% core revenue growth. The acquisitions increased revenues by 2.5%, while the impact of foreign currency translation decreased revenues by 4% during the quarter.

Number of Pages – 39

Contents

Executive Summary

Financial Statements

–Income Statement and Forecast

–Balance Sheet

–Cash Flow

–Q1FY19 Results – Overview

–Q1FY19 – Segment Performance

–FY19 – Guidance and Conclusion

–GAAP to Non-GAAP reconciliation

Historical Performance

–Key Ratios

–Profitability Ratios, Asset Turnover Ratio, Growth Ratio

–Per Share Items and Key Ratios

–Key Balance Sheet and Cash Flow Items

–P/E Band

Product Performance and Key Developments

–Ownership

–Competitors

–Key Developments

Valuation and Consensus Performance

–Relative Valuation

–Analyst Recommendations

Market Price Performance

CrispIdea Coverage Chart

Release Information

  • Released
    :

    June 11, 2019

  • Last Updated
    :

    June 27, 2019